Treatment of lung cancer: will financial issues become a criterion of choice?
Expert Rev Pharmacoecon Outcomes Res. 2013;13(3):273-5.
MeSH terms: Antineoplastic Agents; Europe; Health Care Costs; Humans; Lung Neoplasms; Models, Theoretical; Molecular Targeted Therapy; United States
DOI: 10.1586/erp.13.21